The changing role of beta-blocker therapy in patients with cirrhosis

JOURNAL OF HEPATOLOGY

卷:60

Review

Ge, Phillip S.¹  Runyon, Bruce A.² 

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA

关键词: Beta blockers;    Portal hypertension;    Variceal hemorrhage;    Cirrhosis;    Ascites;   

DOI  :  10.1016/j.jhep.2013.09.016

来源: Elsevier

【 摘 要 】

Cirrhosis is a leading cause of death in the United States and worldwide. Beta-blockers have been established in numerous studies as part of the cornerstone of the medical management of cirrhosis, particularly in the primary and secondary prevention of variceal hemorrhage. However, new evidence has cautioned the use of beta-blockers in patients with end-stage cirrhosis and refractory ascites. In this article, we review the beneficial effects of beta-blocker therapy, the potential harms of aggressive beta-blocker therapy, and provide suggestions regarding the appropriate use of this class of medications in patients with cirrhosis. (C) 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

【 授权许可】

Free